• What's 'in vogue' for chief pharmacy officers

    The term "hospital pharmacy" is becoming a misnomer.
  • How does your system manage rare disease patients? Becker's wants to hear.

    Sponsored
    Fill out this short survey here and attend our annual meeting for free.
  • 11 drugs now in shortage

    In the first three months of 2024, the U.S. reached a record with 323 ongoing medication shortages — the highest number since 2001. 
  • Tower Health taps VP of pharmacy

    West Reading, Pa.-based Tower Health recently promoted Stephanie Goldman, PharmD, from a hospital pharmacy leadership role to a systemwide job. 
  • Walgreens rolls out gene, cell therapy services

    Walgreens is expanding its specialty pharmacy offerings, including gene and cell therapy services, the company said April 25. 
  • 25 most expensive hospital drugs

    Keytruda (pembrolizumab) was nonfederal hospitals' costliest drug expense in 2023, according to research published April 24 in the American Journal of Health-System Pharmacy. 
  • 25 most popular drugs in healthcare

    More than $38 billion was spent in the U.S. on Ozempic and Wegovy (semaglutide) in 2023 — a 100% uptick from 2022 expenditure data, according to research published April 24 in the American Journal of Health-System Pharmacy. 
  • ASHP names candidates for board of directors

    The American Society of Health-System Pharmacists has named eight candidates for its board of directors.
  • Eli Lilly scoops injectable manufacturing site from Nexus

    Eli Lilly will acquire a Wisconsin-based injectable manufacturing facility from Nexus Pharmaceuticals, a drugmaker in Illinois. 
  • ASHP releases toolkit to protect pharmacy residency programs

    For about five years, federal auditors have enforced confusing requirements for residency programs, according to the American Society of Health-System Pharmacists, which released a toolkit April 18 to safeguard these programs. 
  • Emory Healthcare promotes pharmacy leader

    Emory Healthcare recently promoted Ryan Haumschild, PharmD, to the role of vice president of ambulatory pharmacy. 
  • FDA adds new warning to CAR-T therapies

    After investigating the safety of CAR-T cell drugs, the FDA decided to include a serious risk on the boxed warnings of six approved immunotherapies. 
  • Mark Cuban's company ships drugs to CHS

    Community Health Systems' hospitals in Texas and Pennsylvania now stock epinephrine manufactured by Mark Cuban Cost Plus Drug Co.
  • Walgreens pharmacists plan Chicago-area demonstrations

    Nearly 900 pharmacists are planning to demonstrate at 46 Walgreens locations in the Chicago area over the next month. 
  • More CVS pharmacy workers to unionize

    Pharmacy workers at two CVS locations in Rhode Island have filed to unionize. The news comes less than a month after about 30 pharmacists and pharmacy technicians at a Las Vegas CVS Omnicare were the first in the industry to seek unionization. 
  • Lawmakers probe Novo Nordisk over drug's discontinuation

    Senators are demanding to know why Novo Nordisk discontinued Levemir, one of the nation's three long-acting insulins. 
  • Atlantic Health targets polypharmacy

    Morristown, N.J.-based Atlantic Health System will soon deploy an AI-based technology that flags polypharmacy issues, or problems related to taking five or more medications. 
  • The nation's 15 biggest pharmacies

    With $159.4 billion, CVS Health accounts for a fourth of the U.S. pharmacy industry, according to 2023 prescription dispensing revenue data compiled by Drug Channels. 
  • 10 of 20 most popular drugs are in shortage

    In the first quarter of 2024, the U.S. hit a 23-year record after logging 323 active drug shortages. And among GoodRx's list of the nation's 20 most popular therapies, half are in shortage. 
  • Top 15 specialty pharmacies by 2023 revenue

    Two in five accredited specialty pharmacies are owned by hospitals and other healthcare providers, but the nation's three biggest pharmacy benefit managers accounted for 67% of specialty pharmacy revenue in 2023, according to Drug Channels. 
  • Leqembi's rollout becomes a crawl

    About nine months after the FDA fully approved an Alzheimer's drug for the first time, the medicine is trudging through insurance barriers and hesitations from potential patients, the Chicago Tribune reported April 12. 

Featured Whitepapers

Featured Webinars

>